Evidence map›Paper›PMID 32804262›Full record

ArticleEJNMMI research2020

Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model.

Alexander S Pasciak, Sasicha Manupipatpong, Ferdinand K Hui, Larry Gainsburg, Rebecca Krimins, M Christine Zink, Cory F Brayton, Meaghan Morris, Jaime Sage, Danielle R Donahue and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. New frontiers in radioembolization.Therapeutic advances in medical oncology · 2024
    Review
  9. EANM position paper: theranostics in brain tumours-the present and the future.European journal of nuclear medicine and molecular imaging · 2023
    Article
  10. Transarterial Radioembolization: Overview of Radioembolic Devices.Seminars in interventional radiology · 2023
    Review
  11. Article
  12. SIRT in 2025.Cardiovascular and interventional radiology · 2022
    Review
  13. Extrahepatic Applications of Yttrium-90 Radioembolization.Seminars in interventional radiology · 2021
    Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alexander S PasciakSchool of Medicine, The Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA. alexander.pasciak@gmail.com.
Sasicha ManupipatpongSchool of Medicine, The Johns Hopkins University School of Medicine, 1800 Orleans St, Baltimore, MD, 21287, USA.
Ferdinand K HuiDepartment of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Larry GainsburgMid-Atlantic Veterinary Neurology and Neurosurgery, Baltimore, MD, USA.
Rebecca KriminsDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, MD, USA.
M Christine ZinkDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, MD, USA.
Cory F BraytonDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, MD, USA.
Meaghan MorrisDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jaime SageMRI Vets, PLLC, Georgetown, TX, USA.
Danielle R DonahueMouse Imaging Facility, National Institutes of Health, Bethesda, MD, USA.
Matthew R DreherBiocompatibles UK Ltd., a BTG International group company, Farnham, Surrey, UK.
Dara L KraitchmanDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, MD, USA.
Clifford R WeissDepartment of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the safety, feasibility, and preliminary efficacy of yttrium-90 ( MATERIALS: Three healthy research dogs (R1-R3) and five patient dogs with spontaneous intra-axial brain masses (P1-P5) underwent cerebral artery RE with

resultsThe average absorbed dose to treated tissue in R1-R3 was 14.0, 30.9, and 73.2 Gy, respectively, with maximum doses exceeding 1000 Gy. One month after treatment, research dog pathologic analysis revealed no evidence of cortical atrophy and rare foci consistent with chronic infarcts, e.g., < 2-mm diameter. Absorbed doses to masses in P1-P5 were 45.5, 57.6, 58.1, 45.4, and 64.1 Gy while the dose to uninvolved brain tissue was 15.4, 27.6, 19.2, 16.7, and 33.3 G, respectively. Among both research and patient animals, 6 developed acute neurologic deficits following treatment. However, in all surviving dogs, the deficits were transient resolving between 7 and 33 days post-therapy. At 1 month post-therapy, patient animals showed a 24-94% reduction in mass volume with partial response in P1, P3, and P4 at 6 months post-treatment. While P2 initially showed a response, by 5 months, the mass had advanced beyond pre-treatment size, and the dog was euthanized.

conclusionThis proof of concept demonstrates the technical feasibility and safety of

Indexed as

Brain cancerCanine modelGliomaRadiation therapySIRTY90

Identifiers

PMID32804262
PMCPMC7431501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.